March 28th 2024
In a Community Case Forum event in partnership with the Washington State Medical Oncology Society, Bart Scott, MD, broke down various trials of hydroxyurea, ruxolitinib, and interferon in patients with polycythemia vera to assess outcomes such as hematocrit control and molecular response.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Expert Sees Molecular Genetics Increasingly Integrated into Clinical Decision Making in MPNs
September 16th 2017Advancements made in the field of molecular genetics for patients with myeloproliferative neoplasms may be increasingly incorporated into treatment decisions, according to a presentation by Ann Mullally, MD, during the 2017 SOHO Annual Meeting.
Read More
Combination Strategies With Ruxolitinib Explored in Myelofibrosis Treatment
September 15th 2017The treatment of myelofibrosis has changed significantly in the past few years, largely due to the approval of ruxolitinib (Jakafi). Although it provides durable improvements, the JAK inhibitor may be even more effective in combination—as inhibition of JAK-STAT signaling has not shown to be curative.
Read More
Expected Changes to New Guidelines on MPNs Shared
May 19th 2017The NCCN published its first set of guidelines for myeloproliferative neoplasms in October 2016 and is already looking to update and expand these guidelines to match the need for direction in diagnosing and treating patients with MPNs.
Read More
Comparing Hydroxyurea and Pegylated Interferon-Alpha-2a in PV and ET
March 29th 2017John Mascarenhas, MD, associate professor of Medicine, Mount Sinai School of Medicine, discusses the results from the interim analysis of the MPD-RC 112 study, which compared frontline pegylated interferon-alpha-2a (Pegasys) with hydroxyurea in the treatment of patients with high-risk polycythemia vera (PV) and essential thrombocythemia (ET).
Watch
Ruxolitinib Demonstrates Safety, Efficacy in Myelofibrosis, Expanded Access Trial Confirms
February 28th 2017Worldwide clinical experience with the JAK1/2 inhibitor ruxolitinib in patients with myelofibrosis has yielded safety and efficacy data similar to results of a pivotal randomized trial.
Read More